CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun 10, 2022–
CANbridge Pharmaceuticals Inc. (HKEX:1228) , a China and US-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that results from its CAN106 Phase 1 trial were presented at the 2022 European Hematology Association Congress , in Vienna, Austria, on June 10 th.

Read the source article at businesswire.com
2022-06-11 01:00:00